{
    "ticker": "XRTX",
    "name": "XORTX Therapeutics Inc.",
    "description": "XORTX Therapeutics Inc. is a biotechnology company focused on developing innovative therapies for rare and chronic kidney diseases. Founded in 2016, XORTX is committed to addressing significant unmet medical needs in the renal space, particularly conditions such as chronic kidney disease (CKD) and associated complications. The company's lead product candidates aim to harness the therapeutic potential of uric acid modulation to improve kidney function and overall patient outcomes. XORTX has been actively engaged in clinical trials to evaluate the safety and efficacy of its drug candidates, which include XRx-008 and XRx-101, targeting specific mechanisms of kidney injury. The company strives to advance its research and development efforts while fostering collaborations with academic institutions and healthcare organizations to drive innovation. With a dedicated team of professionals and a robust scientific foundation, XORTX Therapeutics is positioned to make a meaningful impact on the lives of patients suffering from kidney diseases, contributing to the broader field of nephrology and enhancing treatment paradigms through its novel therapeutic approaches.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Calgary, Alberta, Canada",
    "founded": "2016",
    "website": "https://www.xortx.com",
    "ceo": "Dr. Allen Davidoff",
    "social_media": {
        "twitter": "https://twitter.com/xortxtherapeutics",
        "linkedin": "https://www.linkedin.com/company/xortx-therapeutics/"
    },
    "investor_relations": "https://www.xortx.com/investors",
    "key_executives": [
        {
            "name": "Dr. Allen Davidoff",
            "position": "CEO"
        },
        {
            "name": "Joni L. S. M. Schaefer",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Drug Candidates",
            "products": [
                "XRx-008",
                "XRx-101"
            ]
        }
    ],
    "seo": {
        "meta_title": "XORTX Therapeutics Inc. | Innovative Kidney Disease Therapies",
        "meta_description": "Explore XORTX Therapeutics Inc., a biotechnology company dedicated to developing novel treatments for kidney diseases. Learn about their innovative drug candidates and commitment to patient care.",
        "keywords": [
            "XORTX Therapeutics",
            "Kidney Disease",
            "Biotechnology",
            "Chronic Kidney Disease",
            "XRx-008",
            "XRx-101"
        ]
    },
    "faq": [
        {
            "question": "What does XORTX Therapeutics focus on?",
            "answer": "XORTX Therapeutics focuses on developing therapies for rare and chronic kidney diseases."
        },
        {
            "question": "Who is the CEO of XORTX Therapeutics?",
            "answer": "Dr. Allen Davidoff is the CEO of XORTX Therapeutics Inc."
        },
        {
            "question": "Where is XORTX Therapeutics headquartered?",
            "answer": "XORTX Therapeutics is headquartered in Calgary, Alberta, Canada."
        },
        {
            "question": "What are XORTX's main drug candidates?",
            "answer": "XORTX's main drug candidates include XRx-008 and XRx-101."
        },
        {
            "question": "When was XORTX Therapeutics founded?",
            "answer": "XORTX Therapeutics was founded in 2016."
        }
    ],
    "competitors": [
        "KPTI",
        "CRMD",
        "AKBA"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "VRTX",
        "BMY"
    ]
}